Kura Oncology (NASDAQ:KURA) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a report published on Friday.

A number of other research firms have also commented on KURA. UBS Group lowered their price target on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a report on Thursday. Scotiabank decreased their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. Bank of America decreased their price objective on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday, November 22nd. BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Finally, Jefferies Financial Group decreased their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, November 21st. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $25.50.

Kura Oncology Trading Down 2.2 %

NASDAQ:KURA opened at $7.53 on Friday. The company has a fifty day moving average of $8.02 and a 200 day moving average of $13.47. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $585.56 million, a P/E ratio of -3.19 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. On average, research analysts predict that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock worth $92,307 in the last three months. 5.50% of the stock is owned by corporate insiders.

Institutional Trading of Kura Oncology

Institutional investors have recently bought and sold shares of the company. Virtus ETF Advisers LLC grew its position in Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after purchasing an additional 3,061 shares during the last quarter. Point72 DIFC Ltd purchased a new stake in Kura Oncology during the 3rd quarter valued at about $146,000. Harbor Advisors LLC purchased a new stake in Kura Oncology during the 4th quarter valued at about $87,000. E Fund Management Co. Ltd. purchased a new stake in Kura Oncology during the 4th quarter valued at about $90,000. Finally, Erste Asset Management GmbH purchased a new stake in Kura Oncology during the 3rd quarter valued at about $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.